» Articles » PMID: 37082361

Endoscopic Diagnosis and Treatment in Gastric Cancer: Current Evidence and New Perspectives

Overview
Journal Front Surg
Specialty General Surgery
Date 2023 Apr 21
PMID 37082361
Authors
Affiliations
Soon will be listed here.
Abstract

Gastric cancer is the fifth most common cause of cancer related deaths worldwide. Despite advancement in endoscopic techniques, the majority of the cases are diagnosed at late stage, when the curative treatment options are very limited. The early gastric cancer (EGC) on the other side is potentially curable, and in selected cases endoscopic resection techniques offer similar survival rates then surgical resection. The detection of EGC is endoscopically challenging and requires high quality examination. Recent data show that close to 10% of the gastric cancer cases had a previous negative endoscopy. This highlights the urgent need to improve the quality of the endoscopy services, what can be achieved by increasing the awareness of gastroenterologists and continuously monitoring the key performance indicators of upper gastrointestinal endoscopy. Newer endoscopic imaging techniques are also becoming commonly available to aid the detection of gastric premalignant lesions and EGC. High-definition endoscopy with image enhancement techniques is preferred over white light endoscopy to recognize these lesions, and they are also useful to determine the invasion depth of EGC. The endoscopic optical characterization of lesions is necessary for the selection of proper resection method and decide whether endoscopic resection techniques can be considered. Artificial intelligence systems aid the detection of EGC and can help to determine the depth of invasion. Endoscopic mucosal resection and endoscopic submucosal dissection requires centralized care and tertiary referral centers with appropriate expertise to ensure proper patient selection, high success rate and low adverse event rate. Appropriately scheduled endoscopic surveillance of high-risk patients, premalignant lesions and after resection of EGC is also important in the early detection and successful treatment of gastric cancer.

Citing Articles

Non-Coding RNA as Biomarkers and Their Role in the Pathogenesis of Gastric Cancer-A Narrative Review.

Bakinowska E, Kielbowski K, Skorka P, Dach A, Olejnik-Wojciechowska J, Szwedkowicz A Int J Mol Sci. 2024; 25(10).

PMID: 38791187 PMC: 11121563. DOI: 10.3390/ijms25105144.


Gender Differences and miRNAs Expression in Cancer: Implications on Prognosis and Susceptibility.

Caserta S, Gangemi S, Murdaca G, Allegra A Int J Mol Sci. 2023; 24(14).

PMID: 37511303 PMC: 10380791. DOI: 10.3390/ijms241411544.

References
1.
Luo H, Xu G, Li C, He L, Luo L, Wang Z . Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019; 20(12):1645-1654. DOI: 10.1016/S1470-2045(19)30637-0. View

2.
Tao M, Zhou X, Hu M, Pan J . Endoscopic submucosal dissection versus endoscopic mucosal resection for patients with early gastric cancer: a meta-analysis. BMJ Open. 2019; 9(12):e025803. PMC: 7008428. DOI: 10.1136/bmjopen-2018-025803. View

3.
Ang T, Pittayanon R, Lau J, Rerknimitr R, Ho S, Singh R . A multicenter randomized comparison between high-definition white light endoscopy and narrow band imaging for detection of gastric lesions. Eur J Gastroenterol Hepatol. 2015; 27(12):1473-8. DOI: 10.1097/MEG.0000000000000478. View

4.
. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2020; 24(1):1-21. PMC: 7790804. DOI: 10.1007/s10120-020-01042-y. View

5.
Wu L, Zhang J, Zhou W, An P, Shen L, Liu J . Randomised controlled trial of WISENSE, a real-time quality improving system for monitoring blind spots during esophagogastroduodenoscopy. Gut. 2019; 68(12):2161-2169. PMC: 6872441. DOI: 10.1136/gutjnl-2018-317366. View